Hologic Announces Fourth Quarter and Fiscal 2009 Operati...(4065 2900 Stock-based com...),Health

Date:11/9/2009

4,065 2,900 Stock-based compensation associated with the termination of former Third Wave officers and acceleration of vesting/modification of the terms of certain equity awards related to the Cytyc merger - 5,405 Operating charges relating to the closure of the Company's organic photoconductor drum coatings manufacturing operations in Shanghai and related costs 2,002 - Restructuring - 6,383 Acquired in-process research and development related to the Third Wave acquisition and the Cytyc merger - 565,200 Income tax effect primarily related to reconciling items (74,899)(2) (65,391)(3) ------- ------- Non-GAAP adjusted net income $301,713 $294,656 ======== ======== EBITDA Non-GAAP adjusted net income $301,713 Interest expense, net 68,341 Provision for income taxes 162,461 Depreciation and amortization not adjusted above 68,332 ------ Adjusted EBITDA $600,847 ======== EXPLANATORY NOTES: (1) Non-GAAP adjusted earnings per share was calculated based on 258,901 and 250,569 weighted average diluted shares outstanding for the twelve months ended September 26, 2009 and September 27, 2008, respectively. (2) To reflect an estimated annual effective tax rate of 35.0% on a non-GAAP basis. (3) To reflect an
'/>"/>

SOURCE Hologic, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Related medicine technology :

1. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
2. ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrigs Disease
3. Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials
4. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
5. Clinical and Histopathological Results Using Pollogens TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser Therapy
6. Hologic Receives CE Marking for the ThinPrep(R) Integrated Imager
7. OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer
8. Hologic Expands Healthcare Investment in Asia
9. Hologic to Host Investor Reception at RSNA 2009
10. Hologic to Present at Citis 2009 Sixth Annual Small/Mid Cap Conference
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients